← ANALYST RATINGS · TIPRANKS
Scholar Rock Holding (SRRK): analyst forecast and price target
Analyst consensus
Strong Buy10 Buy1 Hold0 Sell
Ratings of 11 analysts in the last 3 months · top analysts only12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $72.09, the highest $84.00, the lowest $58.00. The average is +80.7% from the last price of $39.90.
Analyst ratings 18
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | — | Buy | — | Reiterated | 16.10.26on TipRanks 12:25 | −0.7% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $74.00 | Buy | +85.5% | Reiterated | 15.10.26on TipRanks Oct 16 05:20 | +2.3%next day −0.7% | |
| Unknown Analyst | Leerink Partners | $65.00 | Buy | +62.9% | Reiterated | 13.10.26on TipRanks Oct 16 05:20 | −3.4%next day −1.2% | ↗ |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | $77.00 | Buy | +93.0% | Reiterated | 13.10.26on TipRanks 07:50 | −3.4%next day −1.2% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $84.00 | Buy | +110.5% | Reiterated | 12.10.26on TipRanks 09:15 | −0.5%next day −3.4% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $58.00 | Hold | +45.4% | Reiterated | 09.10.26on TipRanks 04:50 | −0.6%next day −0.5% · 5 days −3.5% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $56.00 → $47.00−16.1% | Hold | +17.8% | Reiterated | 06.10.26on TipRanks 02:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $52.00 → $44.00−15.4% | Hold | +10.3% | Reiterated | 06.10.26on TipRanks 02:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $53.00 → $45.00−15.1% | Hold | +12.8% | Reiterated | 06.10.26on TipRanks 02:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $53.00 → $44.00−17.0% | Hold | +10.3% | Reiterated | 06.10.26on TipRanks 02:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $58.00 → $49.00−15.5% | Buy | +22.8% | Reiterated | 06.10.26on TipRanks 02:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $54.00 → $45.00−16.7% | Hold | +12.8% | Reiterated | 06.10.26on TipRanks 02:05 | — | |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $70.00 | Buy | +75.4% | Reiterated | 25.09.26on TipRanks 08:50 | −0.5%next day +1.8% · 5 days −3.5% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $75.00 | Buy | +88.0% | Reiterated | 25.09.26on TipRanks 07:10 | −0.5%next day +1.8% · 5 days −3.5% | ↗ |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | $63.00 → $70.00+11.1% | Buy | +75.4% | Assigned | 21.09.26on TipRanks 06:45 | +1.7%next day +6.3% · 5 days +3.0% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $65.00 → $72.00+10.8% | Buy | +80.5% | Reiterated | 15.09.26on TipRanks 08:10 | −3.1%next day −0.8% · 5 days 0.0% | ↗ |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $65.00 → $70.00+7.7% | Buy | +75.4% | Reiterated | 15.09.26on TipRanks 06:16 | −3.1%next day −0.8% · 5 days 0.0% | ↗ |
| Amy Li★★★★★★★★★★#5687 · hits 36% · avg +7.6% | Jefferies | $57.00 → $65.00+14.0% | Buy | +62.9% | Reiterated | 14.09.26on TipRanks 16:35 | −3.1%next day −0.8% · 5 days 0.0% | ↗ |
| Martin Auster★★★★★★★★★★#1128 · hits 51% · avg +16.1% | Raymond James | $72.00 | Buy | +80.5% | Reiterated | 14.09.26on TipRanks 09:30 | −6.0%next day −3.1% · 5 days −9.0% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | $71.00 | Buy | +77.9% | Reiterated | 14.09.26on TipRanks 02:30 | −6.0%next day −3.1% · 5 days −9.0% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $60.00 | Buy | +50.4% | Reiterated | 13.09.26on TipRanks 21:15 | −6.0%next day −3.1% · 5 days −9.0% | ↗ |
| Gary Nachman★★★★★★★★★★#7384 · hits 47% · avg +0.3% | Canaccord Genuity | $62.00 | Buy | +55.4% | Reiterated | 12.08.26on TipRanks Aug 13 08:40 | +3.1%next day −2.1% · 5 days +5.4% | ↗ |
| Eric Schmidt FCA★★★★★★★★★★#358 · hits 51% · avg +84.1% | Cantor Fitzgerald | — | Buy | — | Reiterated | 19.03.26on TipRanks Mar 20 06:15 | +14.6%next day −0.5% · 5 days −0.9% | ↗ |
| Unknown Analyst | Wolfe Research | $42.00 | Buy | +5.3% | Initiated | 17.11.25on TipRanks 16:25 | +10.0%next day −0.7% · 5 days +1.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Scholar Rock Holding
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $69.81 at a price of $48.32 (+44.5%); now: $69.67 at $39.90 (+74.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 4 | 7 |
| Buy | 21 | 9 | 10 | 16 | 26 | 24 |
| Hold | 0 | 0 | 0 | 0 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.84 (from $-0.94 to $-0.73). Last quarter: $-0.84.
Best top-analyst consensus in the sector · General
About Scholar Rock Holding
- CEO: David L. Hallal
- Employees: 289
- 301 Binney Street, Cambridge, MA, 02142, US
- scholarrock.com
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 22 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗